International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7838665
Original Article
Predisposing Factors for Progression of Hyperbilirubinemia from Low Risk to High Risk in Healthy Full Term Neonates
 ,
 ,
Published
April 18, 2023
Abstract
Introduction: The great burden of neonatal hyperbilirubinemia is exemplified by the fact that globally about 60% of the term and the 80% of preterm babies develop jaundice. Concerns regarding an apparent increase in kernicterus had put forward non invasive new approaches in its prevention and diagnosis in worldwide mainly focusing on body weight loss and feeding pattern in newborns. Objectives: To correlate post natal weight loss with serum bilirubin level during first 72 hours in term newborns and to determine the association of other factors. Method: This prospective observational study included 350 full term neonates who were assessed for clinical jaundice, body weight loss and feeding pattern for the first 72 hours of life. Daily TcB and TSB was done on Day 3. Results: Among the 350 term neonates they were categorized into risk zone based on TSB level in which 217 (62%) were in low, 127 (36%) were in intermediate and 7 (2%) were in high risk zone. The study revealed a significant (p <0.001) difference in mean body weight loss (%) values between these risk groups and can be used as a predictor for significant jaundice (area under roc curve 0.83).The feeding pattern, Kramer’s scale, TcB, urine and stool frequency were also significant (p <0.05) in these groups. Conclusion: Body weight loss percentage can predict neonatal hyperbilirubinemia in the initial 72 hours of life. Other factors were feeding pattern, urine and stool frequency.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
755 Views
381 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved